Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. “Our quarter was hi ...

Core Insights - The report titled "The Cancer Paradox" reveals that oncologists are increasingly encountering advanced-stage cancers, attributing this trend primarily to screening barriers and other factors [3][4][5] - The report highlights the need for improved post-treatment monitoring tools, particularly the emerging ctDNA minimal residual disease (MRD) blood tests, which could enhance early detection of cancer recurrence [3][4][8] Group 1: Oncologists' Perspectives - 76% of oncologists report seeing more advanced-stage cancers, with 75% citing screening barriers as the main cause, followed by aging population (48%) and lifestyle factors (43%) [4][5] - 68% of oncologists believe missed or delayed follow-up care is a significant reason for missed cancer recurrence, while 50% point to imaging tests failing to detect recurrence early enough [5][13] - 94% of oncologists agree that ctDNA MRD testing could reduce delays in diagnosing cancer recurrence, although they face barriers to its widespread adoption [5][8] Group 2: Limitations of Current Monitoring Methods - Traditional methods for monitoring cancer recurrence, such as PET scans and MRIs, are viewed as expensive and invasive, with 50% of oncologists noting that imaging tests often fail to detect recurrence early [6][7] - Nearly all oncologists (96%) believe MRD testing can identify cancer recurrence earlier than current methods, with 89% emphasizing the importance of test sensitivity [7][8] Group 3: Adoption of ctDNA MRD Testing - 88% of oncologists support incorporating MRD testing into standard care for cancer-recurrence monitoring, but over half would be more inclined to recommend it with more clinical evidence, inclusion in clinical guidelines, and better insurance coverage [8][9] - A study published in NEJM found that the Haystack MRD test was a reliable alternative to tissue biopsies, identifying complete responses to immunotherapy faster than traditional imaging methods [9] Group 4: Oncologists' Challenges - 89% of oncologists believe early detection of cancer recurrence can improve outcomes, yet 79% report seeing patients whose recurrence was missed at earlier stages [13] - Anxiety and worry are cited as significant challenges for patients, with 87% of oncologists acknowledging this concern, compared to 53% who mention treatment side effects [13]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:GeneDx Holdings Corp. (WGS) : This genomics-related diagnostic and information services company has seen the Zacks Consensus Estimate for its current year earnings increasing 12.4% over the last 60 days.NatWest Group plc (NWG) : This banking and financial services company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.6% over the last 60 days.Herbalife Nutrition Ltd. (HLF) : This company that offers hea ...

IDEXX Q1 2024 Earnings Highlights (NASDAQ: IDXX) IDEXX Q1 2025 Earnings Highlights (NASDAQ: IDXX) | Revenue | | | Operating | | | Diluted | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | Profit | | | Earnings Per Share | | | | | $998M | | | $317M | | | $2.96 | | | | | Reported growth: | +4% | 31.7% | of Revenue | | | | | | | | | | | | | | Reported growth: | | +5% | | | Organic growth: | +5% | YoY change in basis points: | | | | | | | | | CAG Diagnostics Recurring | | Reported | ...

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Diagnostic Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational c ...

Core Insights - Quest Diagnostics Incorporated reported better-than-expected first-quarter earnings with earnings of $2.21 per share, surpassing the analyst consensus estimate of $2.15 per share [1] - The company achieved quarterly sales of $2.65 billion, exceeding the analyst consensus estimate of $2.63 billion [1] Financial Performance - In the first quarter, Quest Diagnostics experienced strong revenue growth of approximately 12%, including nearly 2.5% in organic growth, attributed to demand recovery in March [2] - The growth was driven by contributions from acquisitions, large enterprise accounts, demand for advanced diagnostics, and expanded health plan access [2] - The company reaffirmed its 2025 revenue guidance of $10.70 billion to $10.85 billion, compared to the consensus of $10.78 billion, and adjusted EPS guidance of $9.55 to $9.80, against the consensus of $9.68 [2] Stock Performance - Following the earnings announcement, Quest Diagnostics shares fell 0.1% to trade at $172.71 [3] - Analysts adjusted their price targets for Quest Diagnostics after the earnings report [3] Analyst Ratings - Baird analyst Eric Coldwell maintained an Outperform rating and raised the price target from $191 to $194 [7] - Evercore ISI Group analyst Elizabeth Anderson maintained an In-Line rating and increased the price target from $175 to $180 [7] - Barclays analyst Stephanie Davis maintained an Equal-Weight rating and raised the price target from $175 to $185 [7] - Truist Securities analyst David Macdonald maintained a Hold rating and increased the price target from $182 to $190 [7]

Financial Data and Key Metrics Changes - In Q4, the company achieved positive and adjusted EBITDA along with positive cash flow, marking a significant milestone towards profitability [9] - Revenue growth for Q4 was nearly 26% compared to the same quarter of the previous year, while full-year revenue growth was close to 22% [14] Business Line Data and Key Metrics Changes - The pathology division's revenues exceeded the breakeven point of $1.3 million per month for the second consecutive quarter, with a target run rate of approximately $25 million by the end of 2025 [16] - The products division's Q4 revenues remained stable at $700,000, with ongoing customer onboarding processes affecting revenue recognition [17][18] Market Data and Key Metrics Changes - The company anticipates a gradual increase in revenue share generated through its distributor network versus direct sales, aiming for scalable growth [37] Company Strategy and Development Direction - The company aims to shift its mindset from a defensive to an offensive approach, viewing expenditures as investments for future growth [13] - A revitalized distribution strategy is in place to create new opportunities for scalable growth beyond direct sales [44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming challenges related to regulatory changes, equipment processes, and personnel issues, emphasizing a proactive approach to customer onboarding [31][32] - The company is focused on enhancing visibility within financial markets and aims to provide clearer insights into its growth trajectory [40][42] Other Important Information - The return of Steve Miller as Chief Commercial Officer is expected to accelerate growth in the products division, leveraging his extensive background in the diagnostic field [35] Q&A Session Summary - No specific questions or answers were provided in the content, thus this section is not applicable.